Vivos Therapeutics, Inc., a medical technology company, engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing, such as mild-to-moderate obstructive sleep apnea (OSA). Its treatment, the Vivos System, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of mild to moderate OSA. Vivos Therapeutics also offers VivoScore, a comprehensive home sleep apnea test. The company markets and sells its Vivos System to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Highlands Ranch, Colorado.
IPO Year: 2020
Exchange: NASDAQ
Website: vivoslife.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/13/2021 | $11.00 → $10.00 | Buy | Roth Capital |
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
4 - Vivos Therapeutics, Inc. (0001716166) (Issuer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
424B3 - Vivos Therapeutics, Inc. (0001716166) (Filer)
EFFECT - Vivos Therapeutics, Inc. (0001716166) (Filer)
POS AM - Vivos Therapeutics, Inc. (0001716166) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
8-K - Vivos Therapeutics, Inc. (0001716166) (Filer)
10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
NT 10-Q - Vivos Therapeutics, Inc. (0001716166) (Filer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $10.00 from $11.00 previously
Roth Capital reiterated coverage of Vivos Therapeutics with a rating of Buy and set a new price target of $11.00 from $12.00 previously
Fastest customizable press release news feed in the world
Vivos adds more cutting-edge products to its roster serving the breathing and sleep wellness market LITTLETON, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on the treatment of breathing related sleep disorders, and SoundHealth, a Silicon Valley based health technology company focused on AI enabled, clinically proven allergy and sleep therapeutics, today announced a collaboration to advance public awareness and access to SoundHealth's consumer-focused airway and sleep health technologies. The collaboration leverages Vivos' extensive national network of over 2,00
LITTLETON, Colo., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced the closing of its previously announced exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023 and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered for resale pursuant to
LITTLETON, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that it has entered into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,982,356 shares originally issued in January 2023, November 2023, and February 20, 2024, at exercise prices ranging from $3.83 to $5.05 per share, at a reduced exercise price of $2.34 per share. The shares of common stock issuable upon exercise of the warrants are registered
LITTLETON, Colo., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company focused on sleep related breathing disorders, including obstructive sleep apnea (OSA), is pleased to announce the grand opening of its latest sleep testing and treatment center near Detroit in Auburn Hills, Michigan. This new center represents an extension of Vivos' sleep center affiliation model—a capital-efficient and scalable version of Vivos' growing operations in Las Vegas, Nevada. This model can take the form of contractual alliances, such as in Auburn Hills, or outright acquisitions of sleep medical practice
LITTLETON, Colo., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced that the Company's CEO Kirk Huntsman and CFO Brad Amman will participate in a fireside chat with Robert Sassoon, senior research analyst of Water Tower Research ("WTR") on Tuesday, December 16, 2025, at 11:00 am ET. Vivos management will discuss the strategic business model pivot and operational execution; the market opportu
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t
LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025. The Company will conduct a conference call at 5:00 pm Eastern time on November 19, 2025, to review the results and provide operational updates.
LITTLETON, Colo., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today released previously unpublished clinical data confirming that treatment with Vivos' FDA-cleared Daytime-Nighttime Appliance (DNA) can provide children with Attention-Deficit/Hyperactivity Disorder (ADHD) and OSA significant relief and improvement in their quality of life. Vivos' DNA appliance is the only FDA 510k cleared non-surgical, non-phar
LITTLETON, Colo., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders, including obstructive sleep apnea (OSA), today announced first time, peer-reviewed published data confirming that the Vivos DNA (Daytime-Nighttime Appliance®) is both safe and efficacious in treating children suffering from OSA. Results from a multicenter clinical trial, now published in the European Journal of Pediatrics, represent a significant milestone in the fight against one of the m
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported
Live Leadership Updates
LITTLETON, Colo., July 30, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (NASDAQ:VVOS) ("Vivos" or the "Company"), a pioneering medical technology company revolutionizing the treatment of obstructive sleep apnea (OSA) and snoring, today announced the appointments of Michael (Mike) E. Bruhn as its Executive Vice President of Business Operations Integration, and Dr. Terry Jones as its new Senior Vice President of Human Resources. These hires demonstrate Vivos' commitment to the successful implementation and expansion of its new sleep testing center and direct patient treatment operations, highlighted by Vivos' recent acquisition of The Sleep Center of Nevada and Vivos' ongoing, active e
Live finance-specific insights
Financial results highlighted by 78% sequential quarter over quarter revenue growth, showing the impact of the first full quarter of Sleep Center of Nevada operations Management to host conference call today at 5:00 pm ET to review results and provide operational updates LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), t
LITTLETON, Colo., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and healthcare services company specializing in the delivery of highly effective diagnostic procedures and proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children), today announced it plans to release its third quarter 2025 financial results after market close today, Wednesday, November 19, 2025. The Company will conduct a conference call at 5:00 pm Eastern time on November 19, 2025, to review the results and provide operational updates.
Quarter highlighted by the key acquisition of The Sleep Center of Nevada, which is generating revenue and seeing strong patient demand for Vivos' differentiated array of highly effective OSA treatments Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today reported
LITTLETON, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults and moderate to severe OSA in children ages 6 - 17), today announced it plans to release its second quarter 2025 financial results after market close today, Tuesday, August 19, 2025. The Company will conduct a conference call at 5:00 pm (Eastern Time) on August 19, 2025, to review the results and provide an overview of the C
Transaction brings OSA diagnostic revenue to Vivos, plus Vivos' highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area Transaction also completes Vivos' business model pivot to target high patient volume centers and higher margin revenues Over $11 million in new financing secured by Vivos, including a senior secured loan from Streeterville Capital and an equity private placement by existing investor New Seneca Partners LITTLETON, Colo., June 11, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leader in delivering and promoting sleep wellness and health through its proprietary, non-invas
Year-over-year product revenue increased 8%, and year-over-year operating expenses decreased 5% as Vivos sets the stage for its Sleep Center of Nevada acquisition and continued advancement of its new marketing and distribution model Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., May 15, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) in adults, and moderate to severe OSA in childr
LITTLETON, Colo., May 14, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17)), today announced it plans to release its first quarter 2025 financial results after market close on Thursday, May 15, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on May 15, 2025 to review the results and provide an overview of the
Year over year product revenue increased 26% Operating expenses declined 21% and year over year operating loss decreased 35% Management to Host Conference Call today at 5:00 pm ET LITTLETON, Colo., March 31, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company'') (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA in adults) and moderate to severe OSA in children ages 6 - 17), today reported financial results and operating highlights for the full year ended D
LITTLETON, Colo., March 28, 2025 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on Monday, March 31, 2025. The Company will conduct a conference call at 5:00 p.m. (Eastern Time) on March 31, 2025 to review the results and provide an overview of the
Revenue Increased 17% Quarter over Quarter Operating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ET LITTLETON, Colo., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ:VVOS), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep-related breathing disorders (including all severities of obstructive sleep apnea (OSA) and snoring in adults and moderate to severe OSA in children ages 6 – 17), today reported financial results and operating highlights for the third quarter and nine months ended September 30, 2024.
This live feed shows all institutional transactions in real time.
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G/A - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)
SC 13G - Vivos Therapeutics, Inc. (0001716166) (Subject)